Skip to main content
PCRX
NASDAQ Life Sciences

Pacira Board Urges Tender as $36.50/Share Viatris Offer Opens, Expires Nov 16

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$36.35
Mkt Cap
$1.451B
52W Low
$18.8
52W High
$36.665
52W Position info
93% above low
Off High info
at 52W high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

PCRX sits 93% above its 52-week low of $18.8.

Summary

Pacira's board unanimously recommends stockholders tender into Viatris' $36.50-per-share all-cash offer, which opened October 30 and expires November 16, 2026, after the HSR waiting period expired October 29.


Key Events · M&A and Partnerships · PCRX

  • Viatris Tender Offer Opens at $36.50

    Viatris' subsidiary is offering $36.50 per share in cash for all Pacira shares; the offer expires at 11:59 p.m. Eastern Time on November 16, 2026, subject to extension.

  • Board Unanimously Recommends Tender

    The board determined the merger is fair and in the best interest of stockholders and recommends tendering; Goldman Sachs' October 8, 2026 opinion calls $36.50 fair from a financial point of view.

  • Antitrust Waiting Period Cleared

    HSR Premerger Notification forms were filed October 14, 2026, and the waiting period expired at 11:59 p.m. Eastern Time on October 29, 2026, with no voluntary timing agreement.

  • CEO Change-of-Control Package $30.1M

    Frank D. Lee's total golden parachute compensation is estimated at $30,132,739, including $24,301,651 of equity; all five named executive officers are disclosed.


Analysis · PCRX · Life Sciences

The Viatris tender offer at $36.50 per share in cash is now formally open, and Pacira's board unanimously recommends that stockholders tender. This is no longer just an announced deal: the HSR antitrust waiting period expired October 29, 2026, and the offer runs to November 16, 2026. The filing also puts hard numbers on insider payouts — CEO Frank D. Lee's change-of-control package totals $30,132,739 — and confirms a $62.0 million termination fee if the board switches to a superior offer. For holders, the practical question is whether to tender into a 45% premium to the $25.20 pre-announcement close or hold for appraisal; with the stock already trading near the $36.50 offer, the remaining return is essentially the deal-completion spread.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCRX was trading at $36.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCRX - Latest Insights

PCRX
Nov 12, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.46
Real-time Price: $36.46 info
Change: $0 (0%) info
Market Cap: $1.462B info
PCRX
Nov 12, 2026, 4:15 PM EST
Filing Type: SC 14D9/A
Importance Score:
7
Price at Filing: $36.46
Real-time Price: $36.46 info
Change: $0 (0%) info
Market Cap: $1.462B info
PCRX
Nov 05, 2026, 4:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.46 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.462B info
PCRX
Nov 05, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.46 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.462B info
PCRX
Oct 13, 2026, 5:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $36.38
Real-time Price: $36.46 info
Change: +$0.080 (+0.22%) info
Market Cap: $1.462B info